Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens
Heewon Jang, Ji-Eun Chang, Anke Wilhelm · 2025
Read Strategic Combinations of Antibody–Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens by Heewon Jang, Ji-Eun Chang, Anke Wilhelm (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12737156.txt.
Description
Heewon Jang, Ji-Eun Chang, and Anke Wilhelm review how antibody-drug conjugates are being combined with other cancer treatments. Their review came out in 2025. These conjugates pair an antibody that homes to tumor cells with a poison it delivers inside, sparing most healthy tissue.
Fifteen such drugs had won approval in the United States by 2025, with one later withdrawn for safety. Interest has moved beyond single-drug use toward combinations with chemotherapy, immune checkpoint drugs, and targeted agents. Several pairings already hold approvals or sit in late-stage trials. Multi-drug regimens are gaining ground on the older two-drug pattern. The authors organize recent advances by regimen type, focusing on combinations built around approved conjugates across many cancers.
Catalog record
| CREATOR | Heewon Jang, Ji-Eun Chang, Anke Wilhelm |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 127 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |